The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
News|Articles|May 1, 2025
OncLive’s FDA Approval Report: The Regulatory Rundown for April 2025
Author(s)Kristi Rosa
Here is your snapshot for all therapeutic options that were cleared by the FDA in April 2025 spanning tumor types.
Advertisement
Advertisement
Below is your guide to all the oncologic therapeutic options approved by the FDA in April 2025. The roundup provides everything you need to know, right at your fingertips—all the topline findings that supported the decisions and expert insights detailing what they mean for clinical practice.
Related to this article
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Pelareorep plus a checkpoint inhibitor earned FDA fast track designation for pretreated, inoperable, recurrent, or metastatic squamous cell anal carcinoma.
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Iza-bren was approved in China for recurrent or metastatic ESCC following progression on platinum-based chemotherapy and PD-1/PD-L1 inhibition.
Catch up on insights into the global development of breast cancer treatments in the global spotlight.
Advertisement
Advertisement